Press coverage about Checkpoint Therapeutics (NASDAQ:CKPT) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 48.291196417549 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/25/checkpoint-therapeutics-ckpt-getting-somewhat-favorable-media-coverage-analysis-finds.html.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Receive News & Ratings for Checkpoint Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.